請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78635
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 余宏政(Hong-Jeng Yu) | |
dc.contributor.author | Ming-Chih Lai | en |
dc.contributor.author | 賴明志 | zh_TW |
dc.date.accessioned | 2021-07-11T15:08:49Z | - |
dc.date.available | 2021-08-01 | |
dc.date.copyright | 2019-08-28 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-13 | |
dc.identifier.citation | 1. Abarbanel J, Marcus EL. Impaired detrusor contractility in community-dwelling elderly presenting with lower urinary tract symptoms. Urology. 2007 Mar;69(3):436-40. Abdel-Meguid TA, Tayib A, Al-Sayyad A. Tamsulosin to treat uncomplicated distal ureteral calculi: a double blind randomized placebo-controlled trial. Can J Urol. 2010 Jun;17(3):5178-83.
2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78. 3. Akkoç Y, Bardak AN, Ersöz M, Yılmaz B, Yıldız N, Erhan B, Tunç H, Koklu K, Alemdaroğlu E, Dogan A, Ozisler Z, Koyuncu E, Şimşir Atalay N, Gündüz B, Işık R, Güler A, Sekizkardeş M, Demir Y, Yaşar E, Sasmaz E, Şatır Ö. Post-stroke lower urinary system dysfunction and its relation with functional and mental status: a multicenter cross-sectional study. Top Stroke Rehabil. 2019 Mar;26(2):136-141. 4. Alam S, Moodie EEM, Stephens DA. Should a propensity score model be super? The utility of ensemble procedures for causal adjustment. Stat Med. 2019 Apr 30;38(9):1690-1702. 5. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, Wong TY, McNeil J, Shaw JE. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007 Jul 10;116(2):151-7 6. Beaumont T. Prevalence and outcome of postpartum urinary retention at an Australian hospital. Midwifery. 2019 Mar;70:92-99. 7. Bøje CR, Dalton SO, Primdahl H, et al. Evaluation of comorbidity in 9388 head and neck cancer patients: a national cohort study from the DAHANCA database. Radiother Oncol 2014;110:91–7. 8. Brown JS, Grady D, Ouslander JG, et al. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart & Estrogen/ Progestin Replacement Study (HERS) Research Group. Obstet Gynecol 1999; 94:66–70. 9. Chang C, Lu F, Yang YC, Wu JS, Wu TJ, Chen MS, Chuang LM, Tai TY. Epidemiologic study of type 2 diabetes in Taiwan. Diabetes Res Clin Pract. 2000 Oct;50 Suppl 2:S49-59 10. Chang SJ, Chiang IN, Yu HJ. The effectiveness of tamsulosin in treating women with voiding difficulty. Int J Urol. 2008 Oct;15(11):981-5. 11. Changxiao H, Zhengyong Y, Shibing Y, Caiwen W, Yingchuan H, Wei H, Hanhui W, Dong L, Peng H, Jing L, Rui Z, Jia L, Hong S. Clinical and urodynamic evaluation of women referred with diabetes mellitus. Int Urogynecol J. 2014 Jul;25(7):979-83 12. Daneshgari, F., Liu, G., Birder, L., Hanna-Mitchell, A. T., & Chacko, S. (2009). Diabetic bladder dysfunction: Current translational knowledge. The Journal of Urology, 182, S18–S26. 13. Dereli Yilmaz S, Demirgoz Bal M, Celik S, Rathfisch G, Kizilkaya Beji N, Dinccag N, Yalcin O. Lower Urinary Tract Symptoms in Women With Type 2 Diabetes Mellitus. J Wound Ostomy Continence Nurs. 2016 Sep-Oct;43(5):523-8. 14. Fayyad AM, Hill SR, Jones G. Prevalence and risk factors for bothersome lower urinary tract symptoms in women with diabetes mellitus from hospital-based diabetes clinic. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Nov;20(11):1339-44. 15. Gaitonde S, Malik RD, Christie AL, Zimmern PE. Bethanechol: Is it still being prescribed for bladder dysfunction in women? Int J Clin Pract. 2018 Aug 15:e13248. 16. Goldman HB, Appell RA. Voiding dysfunction in women with diabetes mellitus. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(2):130-3.. 17. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005 Jan;28(1):164-76. 18. Hill SR , Fayyad AM , Jones GR . Diabetes mellitus and female lower urinary tract symptoms: a review . Neurourol Urodyn . 2008 ; 27 : 362-367 . 19. Hsiao F, Yang C, Huang Y, et al. Using Taiwan’s national health insur¬ance research databases for pharmacoepidemiology research. J Food Drug Anal. 2007;15(2):99. 20. Jiang YD, Chang CH, Tai TY, Chen JF, Chuang LM. Incidence and prevalence rates of diabetes mellitus in Taiwan: analysis of the 2000-2009 Nationwide Health Insurance database. J Formos Med Assoc. 2012 Nov;111(11):599-604. 21. Kebapci N, Yenilmez A, Efe B, Entok E, Demirustu C. Bladder dysfunction in type 2 diabetic patients. Neurourol Urodyn. 2007;26(6):814-9. 22. Kietpeerakool C, Aue-Aungkul A, Galaal K, Ngamjarus C, Lumbiganon P. Nerve-sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical cancer (stage Ia2 to IIa). Cochrane Database Syst Rev. 2019 Feb 12;2:CD012828. 23. Lee WC, Wu HP, Tai TY, Yu HJ, Chiang PH. Investigation of urodynamic characteristics and bladder sensory function in the early stages of diabetic bladder dysfunction in women with type 2 diabetes. J Urol. 2009 Jan;181(1):198-203. 24. Lin YH, Hou CP, Chen TH, Juang HH, Chang PL, Yang PS, Lin YS, Chen CL, Tsui KH. Is diabetes mellitus associated with clinical outcomes in aging males treated with transurethral resection of prostate for bladder outlet obstruction:implications from Taiwan Nationwide Population-Based Cohort Study. Clin Interv Aging. 2017 Mar 16;12:535-541. 25. Poetter CE, Stewart JT. Treatment of clozapine-induced constipation with bethanechol. J Clin Psychopharmacol. 2013 Oct;33(5):713-4 26. Quadri SA, Farooqui M, Ikram A, Zafar A, Khan MA, Suriya SS, Claus CF, Fiani B, Rahman M, Ramachandran A, Armstrong IIT, Taqi MA, Mortazavi MM. Recent update on basic mechanisms of spinal cord injury. Neurosurg Rev. 2018 Jul 11. doi: 10.1007/s10143-018-1008-3. 27. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004 Mar;171(3):1029-35. 28. Robinson D, Staskin D, Laterza RM, Koelbl H. Defining female voiding dysfunction: ICI-RS 2011. Neurourol Urodyn. 2012 Mar;31(3):313-6. 29. Sveinbjornsdottir S. The clinical symptoms of Parkinson's disease. J Neurochem. 2016 Oct;139 Suppl 1:318-324. 30. Tai HC, Tai TY, Yang WS, Wang SW, Yu HJ. Associations between lower urinary tract dysfunction and glycemic control in women with type 2 diabetes: A cross-sectional study. J Diabetes Complications. 2016 Apr;30(3):415-9. 31. Yang Z, Dolber PC, Fraser MO. Diabetic urethropathy compounds the effects of diabetic cystopathy. J Urol. 2007 Nov;178(5):2213-9. 32. Yu HJ, Lee WC, Liu SP, Tai TY, Wu HP, Chen J. Unrecognized voiding difficulty in female type 2 diabetic patients in the diabetes clinic: a prospective case-control study. Diabetes Care. 2004 Apr;27(4):988-9. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78635 | - |
dc.description.abstract | 目標
本研究是在13年的期間內,評估第二型糖尿病女性患者的嚴重排尿障礙(VD)的發生率和風險。 研究材料和方法 這份世代群組研究使用了台灣全民健保研究資料庫(National Health Insurance Research Database, NHIRD)的資料,從2001年到2013年中,找出新診斷的第二型糖尿病患者(DM世代群組),以及符合年齡、共病現象和Charlson共病指標(CCI)分數的患者(非DM世代群組)。嚴重VD的定義為膀胱排尿有困難,需要bethanechol或tamsulosin的治療。對於嚴重VD的發生率,我們調查到2013年底為止。據此計算出嚴重VD的發生率(每年每一萬人),並使用Cox比例風險迴歸模型(Cox proportional hazards regression model)估算風險比例。使用Kaplan-Meier法(Kaplan-Meier),在兩個世代群組中,繪製出嚴重VD的累積發生率圖形。 結果 在13年期間,第二型糖尿病女性患者的嚴重VD發生率為1.42%。DM世代群組和非DM世代群組共納入34,125位病患。嚴重VD發生率在DM世代群組和非DM世代群組中,分別約為有20.0位和11.4位(每年每一萬人)。針對混擾因子進行修正後,可以推算出,第二型糖尿病女性患者的嚴重VD發生率風險增加1.79倍。在10年的後續追蹤期間,DM世代群組的嚴重VD累積發生率顯著較高(2.01% vs. 1.07%, p<0.0001)。 結論 對於女性,第二型糖尿病和嚴重VD的風險上升有關聯性。因此,臨床醫師應該教育女性病患,使其了解第二型糖尿病和嚴重VD之間的關聯性。 | zh_TW |
dc.description.abstract | Objective:
To evaluate the incidence and risk of significant voiding dysfunction (VD) in women with type 2 diabetes during a 13-year study period. Materials and methods: This cohort study utilized data from the National Health Insurance Research Database (NHIRD) of Taiwan to identify patients with type 2 diabetes (DM cohort) and age-, comorbidity-, and Charlson comorbidity index (CCI) score-matched cohort (non-DM cohort) from 2001 to 2013. Significant VD was defined as difficulty in bladder emptying requiring bethanechol or tamsulosin treatment. Significant VD occurrence was monitored until the end of 2013. Incidence rate of significant VD (per 10,000 person-years) was calculated, and hazards ratios were estimated using Cox proportional hazards regression models. Cumulative incidence of significant VD in both cohorts were plotted using the Kaplan-Meier method. Results Incidence of significant VD in women with type 2 diabetes is 1.42% during a 13-year period. A total of 34,125 patients were selected for the DM and non-DM cohorts, respectively. Incidence rates of significant VD were approximately 20.0 and 11.4 per 10,000 person-years for the DM and non-DM cohorts, respectively. After adjusting for potential confounders, a 1.79-fold increased risk of significant VD was observed in women with type 2 diabetes. Cumulative incidence of significant VD was significantly higher in the DM cohort at the 10-year follow-up (2.01% vs. 1.07%, p<0.0001). Conclusion Type 2 diabetes is independently associated with increased significant VD risk in women. Therefore, clinicians should be aware of and educate female patients about the association between type 2 diabetes and significant VD. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T15:08:49Z (GMT). No. of bitstreams: 1 ntu-108-P01421017-1.pdf: 679187 bytes, checksum: 0f7b94636cabd95e78ed03c2692386ba (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員會審定書 1
誌謝 4 中文摘要 5 英文摘要 7 碩士論文內容 1. Introduction 9 1.1 Background 9 1.2 Objectives 9 2. Materials and methods 10 2.1 Data source 10 2.2 Study design 11 2.3 Study participants 11 2.4 Statistical analysis 12 3. Results 12 3.1 Participants and descriptive data 12 3.2 Main results 13 3.3 The analysis of subgroups 14 3.4 The analysis of new users of bethanechol, tamsulosin or combination therapy 14 4. Discussion 15 4.1 The interpretation of our database 15 4.2 Summarize main results 15 4.3 The interpretation of results of subgroup analysis 17 4.4 Summarize the trend of new users of bethanechol, tamsulosin or combination therapy 18 4.5 Limitations 19 5. Conclusion 20 6. Future perspectives 20 7. References 22 8. Figures and tables 27 Figure 1. Flowchart showing the study participant selection 27 Table 1. Characteristics between patients with and without DM 28 Table 2. Incidence rates and hazard ratios (HR) of significant VD for DM and potential risk factors in multivariate cox regression model analysis 30 Table 3. Subgroup analysis for incidence and hazard ratio (HR) of significant VD between patients with and without DM, stratified by age and CCI 32 Figure 2. Kaplan-Meier probability for DM and non-DM patients with significant VD 34 Figure 3. The number of new users of bethanechol, tamsulosin, or combination therapy by year 35 Appendix 36 | |
dc.language.iso | en | |
dc.title | 第二型糖尿病女性患者的嚴重排尿障礙發生率較高:根據全國人口所進行的世代研究 | zh_TW |
dc.title | Women with type 2 diabetes are associated with higher incidence of significant voiding dysfunction:
A nationwide population-based cohort study | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 陳祈玲(Chi-Ling Chen) | |
dc.contributor.oralexamcommittee | 黃昭淵(Chao-Yuan Huang),廖俊厚(Chun-Hou Liao) | |
dc.subject.keyword | 糖尿病,排尿障礙,發生率,女性,台灣, | zh_TW |
dc.subject.keyword | diabetes mellitus,voiding dysfunction,incidence,women,Taiwan, | en |
dc.relation.page | 36 | |
dc.identifier.doi | 10.6342/NTU201902670 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-08-13 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-P01421017-1.pdf 目前未授權公開取用 | 663.27 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。